CClinicalTrials.gg
Status unknownNCT04171882Updated Nov 23, 2021

Microglial Cells Activation Imaging Using PET-CT With 18F-DPA714

An observational study in Microglial Cells Activation Imaging, sponsored by Weibing Miao, PhD. Status unknown at 2 sites in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by Weibing Miao, PhD · Observational

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 80 Years
Sex
All
01

Study summary

There is accumulating evidence suggesting that inflammatory processes, through microglial activation, would play a key role in brain injury and degeneration. It is considered that microglial activation would be part of self-propelling cycle of neuroinflammation that fuels Neurologic deterioration. It is however hard to evidence microglial activation in vivo: first, the investigators need very high-resolution imaging tools and then, the only ligand available to date, 11C-PK11195, has a low sensitivity and specificity and provided heterogeneous results. 18F-DPA-714 is a new PET ligand which labels microglial cells. The investigators aim to explore the clinical feasibility used PET-CT with 18F-DPA714 to monitor microglial cells activation of brain in several different disease. This study might reveal significant neuroinflammatory process in the brain. The results of this study might provide a new biomarker of disease pathological progression and help as identifying subjects who might most benefit from a specific anti-inflammatory drug.

02

Conditions studied

  • Microglial Cells Activation Imaging
03

In context

Lead sponsor

Weibing Miao, PhD is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with neurological or psychiatry diseases or known brain lesion

Inclusion criteria

  • Age > 18 years
  • Positron emission tomography scans were acquired more than twice
  • Written informed consent was provided by the patients and their health care proxies -

Exclusion criteria

Exclusion Criteria:

  • Contraindication for PET examination
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Standardized Uptake Value (SUV)

    Measures of specific binding of 18F-DPA-714 measures of specific binding of the tracer

    Time frame: 2 years

07

Study locations

2 of 2 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04171882
Lead sponsor
Weibing Miao, PhD
Responsible party
Weibing Miao, PhD (professor, First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
Nov 21, 2019
Start date
Nov 1, 2019
Primary completion
Nov 1, 2024 (estimated)
Completion
Nov 1, 2024 (estimated)
Last update
Nov 23, 2021

Study contacts

fu ying, PhD
Contact
fuying1995@163.com
13920263588 ext. 13920263588

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion